Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

A unique feature of HR is that it repairs the damage to the DNA in a highly accurate way. In eukaryotic cells (those with a ...

The proteinase k market is expected to reach approximately USD 30.2 million in 2025 and expand to around USD 48.2 million by 2035, reflecting a compound annual growth rate (CAGR) of 4.8% over the ...